Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab with CyBorD in newly diagnosed multiple myeloma
NCT02955810Phase 1Unknown
- Sponsor
- University of Galway
- Start
- Nov 2016
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University of Galway. Primary endpoints: Maximum Tolerated Dose at 15 months and Complete Response rate post Autologous Stem Cell Transplantation at 42 months. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02955810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955810.